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Abstract
Ceftriaxone treatment of bacterial infections can be associated with 
biliary complications, more commonly in children than adults, in a dose-
dependent manner. This study describes a clinical case series of children with 
ceftriaxone-related cholelithiasis.
We performed a retrospective analysis of cases of ceftriaxone-related 
biliary complications admitted to the Pediatric Clinic, Department of Clinical 
and Experimental Medicine, University of Sassari, Italy, during the period 
2005-2015.
Four children with cholelithiasis occurring during, or soon after, the 
treatment with ceftriaxone are reported. Case 1 (6-month-old), case 2 (9-year-
old) and case 4 (10-year-old) were symptomatic, while case 3 (3-year-old) 
was asymptomatic. After the ultrasonographic diagnosis of gallstones 
(cases 1 and 2) or biliary sludge (cases 3 and 4), ceftriaxone treatment was 
withdrawn, and ursodeoxycholic acid (UDCA) was started in cases 1 and 2. 
A complete recovery was observed in all but case 1, in whom cholelithiasis 
was still detectable at one-year follow-up by ultrasonography. This case 
underwent a triple antibiotic protocol for bacterial meningitis. The protocol 
included rifampicin, which is known to have an effect in decreasing hepatic 
concentration of bile salts. Therefore, in this case, both rifampicin and UDCA 
were of no benefit in preventing or treating ceftriaxone biliary complications. 
The current pharmacological approach for the treatment of ceftriaxone-
related cholelithiasis seems to be ineffective, likely due to the high calcium 
content of gallstones. Therefore, the best strategy of intervention for 
ceftriaxone biliary complications in children remains the prevention of the 
risk factors.
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Introduction
Cholelithiasis and biliary sludge (BS) are two 
uncommon conditions in childhood, even though 
the identification of these disorders has increased 
in the last decades [1-6].
Ceftriaxone, a semi-synthetic third-generation 
cephalosporin, is the principal causative agent of 
drug-induced cholelithiasis in pediatric practice 
[7, 8]. Following administration by parenteral 
route, preferably intravenously, it is widely 
distributed in most body tissues and fluids. Unlike 
most other cephalosporins (excluding cefotaxime), 
ceftriaxone penetrates the meninges, particularly 
when they are inflamed. Partially metabolized, it is 
mainly excreted through the urine (60-70%), and 
to a lesser extent in the bile (40%), where it can 
achieve concentrations 20- to 150-fold higher than 
in the blood, possibly resulting in the precipitation 
of ceftriaxone-calcium salts [9].
Ceftriaxone has a long half-life ranging from 9 
to 15 hours in the neonatal period, while is about 
8 hours at older ages. For this reason, it can be 
administered once daily for most infections except 
meningitis, where an every 12-hour regimen is 
required [10]. Depending on the severity of the 
disease, ceftriaxone dosage ranges from 50 to 100 
mg/kg/day in children up to 12 years old, and 1 to 
2 g/day in children aged 12 years or older.
As regards tolerability, the most common 
adverse effects of ceftriaxone are gastrointestinal 
and cutaneous [11, 12]. Systemic anaphylaxis 
is very uncommon, with an estimated risk of 
0.0001% to 0.1%. Thrombocytosis, leukopenia 
and liver function test alterations may be observed 
in less than 5% [11]. Among the adverse effects of 
ceftriaxone are cholelithiasis and BS [12], and more 
rarely also self-limited nephrolithiasis [13, 14], all 
favored by its excretion at high concentrations. 
Ceftriaxone can interact with calcium leading to 
calcium-ceftriaxone precipitation [15], in preterm 
and term neonates resulting in severe reactions, 
including death [16, 17]. 
Cholelithiasis ceftriaxone-associated is usually 
defined as “biliary pseudolithiasis” (BP) or 
“reversible cholelithiasis” because it is a transient 
condition, which resolves after discontinuation 
of treatment. The incidence of this condition is 
variable, ranging between 8.6% and 57.5% in the 
pediatric population [3-5, 9, 12, 13], attributable 
to multiple factors that may influence the onset of 
this condition. The BS is more common among 
younger patients, and seems to be dose-dependent, 
as it is more frequent in children who receive a 
higher weight-dosage than adults, and favored by 
a high infusion rate: a short bolus infusion over 
3-5 minutes is associated with a higher incidence 
compared to the administration in 30 minutes [12]. 
Restriction of oral intake and fasting are other risk 
factors for BP in children, because of their capacity 
to cause gallbladder dysfunction and biliary stasis. 
According to Shiffman et al. [18], a high dosage 
of ceftriaxone can result in BS in children with 
impaired gallbladder emptying. 
All conditions able to interfere with bile flow 
(fasting, total parenteral nutrition, etc.) or with 
ceftriaxone excretion (renal failure, high dose 
or long-term treatment, surgery) might lead to 
an abnormal concentration of this medication in 
the biliary tract resulting in an increased risk of 
developing BS or BP.
The BS and BP occur within 2-9 days after 
initiation of therapy and usually resolve within 
8-23 days after therapy discontinuation [19]. 
Currently, no clear recommendations are 
available concerning the management of pediatric 
ceftriaxone-related BP [3]. In this article, we 
performed a retrospective analysis of children with 
ceftriaxone-related biliary complications admitted 
to the Pediatric Clinic, Department of Clinical and 
Experimental Medicine, University of Sassari, 
Italy, during the period 2005-2015.
Clinical cases
Four cases of ceftriaxone-associated cho le-
lithiasis and/or BS were identified during the 
study period. Demographic characteristics, dosage 
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and duration of ceftriaxone treatment, and biliary 
complications are summarized in Tab. 1, while 
Tab. 2 shows the ultrasonographic features and 
pharmacological treatment of ceftriaxone-induced 
cholelithiasis at the diagnosis and during the 
follow-up. 
Case 1
A 6-month-old boy was admitted to hospital 
for acute meningococcal meningitis and started 
therapy with high dose i.v. ceftriaxone (100 mg/
kg/day), i.v. vancomycin (40 mg/kg/day), and oral 
rifampicin (20 mg/kg/day). 
During hospitalization, abdominal ultrasounds 
(US) evaluation, performed due to the persistence 
of emesis, showed a regular gallbladder with 
thickened walls and the presence of at least two 
gallstones of 7 and 9 mm, respectively. At the 12th 
day of treatment, ceftriaxone was discontinued 
and ursodeoxycholic acid (UDCA) was started and 
maintained for 6 months at the dose of 10 mg/
kg/day. At 1-year follow-up, the child appeared 
in good general health, and the ultrasonography 
showed only one small gallstone of 3.7 mm located 
at the infundibulum, despite UDCA treatment. 
Case 2
A 9-year-old girl was admitted to hospital for 
suspected adenomesenteritis with upper airways 
bacterial infection. On admission, laboratory and 
instrumental examinations (abdominal US) were 
normal (Fig. 1A). Because of the worsening of 
abdominal pain, antibiotic therapy with ceftriaxone 
was undertaken and fasting was started. After an 
initial improvement of symptoms abdominal pain 
recurred, therefore laboratory tests and abdominal 
US were repeated, revealing consistent with 
acute cholecystitis. Ceftriaxone was replaced 
by piperacillin, and ranitidine and paracetamol 
were started. A gradual clinical improvement was 
observed until complete resolution of symptoms. 
After 2 days of ceftriaxone discontinuation, US 
examination showed the presence of gallstones 
and BS (Fig. 1B and Fig. 1C). For this reason, 
UDCA therapy was maintained for 3 months. 
After 1 month, US imaging showed a complete 
resolution of BP.
Case 3 
A 3-year-old girl came to our observation for 
Influenza B infection complicated by acute otitis 
media and severe gastroenteritis. Intravenous 
fluid therapy was started with little benefit, as 
anorexia, vomiting and diarrhea did not improve. 
For this reason, ceftriaxone treatment was started 
on the 9th day of hospitalization. Laboratory 
examinations showed high γ-glutamyl transferase 
serum levels (5 times upper normal level) with 
mild hypertransaminasemia (both AST and ALT 
1.5 times upper normal levels). Abdominal US 
demonstrated the presence of BS (Fig. 1D). 
Table 1. Main demographic characteristics, ceftriaxone treatment and biliary complications in the 4 patients.
Case Age Sex
Ceftriaxone therapy Biliary complications
Dose  
(mg/kg)
Duration 
(days) Onset Symptoms Type
1 6 months M 100 12 Not known Vomiting Gallstones
2 9 years F 65 3 2nd day Abdominal pain and nausea Gallstones
3 3 years F 70 4 Not known None BS
4 10 years M 50 6 1 week after Heartburn (with irradiation to right shoulder) and nausea BS
BS: biliary sludge.
Case Abdominal US at the diagnosis Pharmacological treatment Abdominal US at follow-up
1 Thickened gallbladder walls and gallstones of 7-9 mm
Oral UDCA (10 mg/kg/day)
Oral rifampicin a (20 mg/kg/day)
Reduction of gallstones number and 
size (3.7 mm) 1 year later
2 Gallstones of about 2-5 mm Oral UDCA (10 mg/kg/day) No gallstones at 3-month follow-up
3 BS None Not performed
4 BS None No gallstones at 10-day follow-up
US: ultrasounds; UDCA: ursodeoxycholic acid; BS: biliary sludge.
a Prescribed for the treatment of bacterial meningitis.
Table 2. Ultrasonographic features and pharmacological treatment of ceftriaxone-induced cholelithiasis at the diagnosis 
and at follow-up.
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Therefore, ceftriaxone therapy was discontinued 
while the infusion support was maintained. In 
the following days, resumption of appetite and 
complete clinical recovery were observed. 
Case 4
A 10-year-old boy was admitted to hospital 
for profuse diarrhea, severe abdominal pain 
associated with bacterial tonsillitis. On admission, 
the patient presented with dehydration and a mild 
increase in serum total bilirubin (2.1 mg/dl). 
Molecular analysis of the UGT1A1 gene revealed 
a homozygous genotype compatible with Gilbert’s 
syndrome [20]. Treatment consisted of i.v. fluid 
support and antibiotic therapy with ceftriaxone. 
The patient was discharged on the 6th day of 
hospitalization. During the follow-up, heartburn 
with right shoulder irradiation and nausea were 
reported. Abdominal US scan revealed the 
presence of BS (Fig. 1E), while laboratory tests 
showed reduced serum total bilirubin (1.2 mg/
dl), hypertransaminasemia (AST 1.5 times upper 
normal level; ALT 5 times upper normal level) and 
increased serum levels of γ-glutamyl transferase 
(1.5 times upper normal level). Ten days later, a 
subsequent US scan showed the disappearance 
of BS along with the resolution of associated 
symptoms. 
Discussion
Ceftriaxone is a cephalosporin extensively used 
in daily practice, especially in childhood, due to 
its efficacy, safety and long half-life. Ceftriaxone-
related BP is an important cause of abdominal pain 
in children undergoing such therapy.
It has been shown that ceftriaxone-related 
cholelithiasis is a condition benign and reversible 
with discontinuation of therapy, within 15 days on 
average [12]. If this complication is suspected, an 
abdominal US should be performed. A conservative 
approach is advocated and surgery is usually not 
necessary [3].
In our clinical case series, the youngest patient, 
aged 6 months, was under triple-antibiotic therapy 
for bacterial meningitis while the other 3 children 
were treated with ceftriaxone for less severe 
bacterial infections. Ceftriaxone therapy was given 
at high doses in all patients, and the length of 
Figure 1. A. Case 2: abdominal ultrasounds (US) at hospital admission (before ceftriaxone treatment) shows a normal 
gallbladder. B-C. Case 2: abdominal US during ceftriaxone treatment shows gallstones of about 2 and 5 mm (B) and biliary 
sludge (BS) (C), respectively. D. Case 3: BS. E. Case 4: BS.
A. B. C.
D. E.
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treatment ranged from 3 to 12 days. Three children 
complained cholelithiasis clinical symptoms, 
while one was asymptomatic. Therefore, both 
symptomatic and asymptomatic presentations were 
observed, as reported by other authors [3-6]. In the 
only asymptomatic patient, laboratory findings of 
elevated liver enzymes led to further investigation 
by abdominal US. In all cases, abdominal US 
revealed BP or BS, and thus ceftriaxone therapy 
was promptly discontinued. Two patients (cases 
1 and 2) received UDCA for a period of 6 and 3 
months, respectively. The complete recovery after 
therapy withdrawal was observed in all but one case. 
In this latter case, cholelithiasis developed during 
ceftriaxone treatment, with a subsequent reduction 
but not a complete clearance at 1-year follow-up.
By chance, one of our cases underwent the 
combined use of rifampicin, prescribed as part of 
the triple antibiotic protocol for bacterial meningitis 
treatment, along with UDCA. Rifampicin is known 
to have an effect in decreasing hepatic concentration 
of bile salts [21]. In this child, cholelithiasis, even 
if reduced, was still detectable at US at 1-year 
follow-up, despite rifampicin and UDCA treatment. 
Combined use of rifampicin and UDCA has been 
recently proposed for the treatment of advanced 
cholestatic liver disease: their mechanisms of 
action have been described to be independent and 
complementary [22], but without synergic effects 
on the hepatobiliary system [23]. In pediatric 
cholestasis, rifampicin has application mainly as 
anti-pruritic agent [21]. This mechanism of action is 
exerted: (1) by enhancing bilirubin elimination at the 
canalicular membrane and at the intestinal mucosa; 
(2) by stimulating the hepatic detoxification CYP-
3A4 and UGT1A1 enzymes [22]. In contrast, UDCA 
acts mostly on the expression of hepato-biliary 
ABC transporter proteins [22]. Moreover, higher 
UDCA concentration in the bile would determine 
a significant reduction of bile lithogenic index [22]. 
Based on our results, the efficacy of UDCA for the 
treatment of ceftriaxone-related BP is questionable 
and not predictable. The high content of calcium is 
likely the reason for the lack of efficacy of current 
pharmacological approach for the treatment of this 
condition. 
Conclusions
Ceftriaxone is an important causative agent of 
BP and BS in pediatric practice. These adverse 
effects are dose-dependent and result from the 
biliary drug excretion at high concentrations.
The current pharmacological approach for the 
treatment of ceftriaxone-related cholelithiasis 
seems to be ineffective, likely due to the high 
calcium content of gallstones. Therefore, the best 
strategy of intervention for ceftriaxone hepato-
biliary complications in children remains the 
prevention of the risk factors.
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